StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

by · The Cerbat Gem

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research report sent to investors on Monday. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Down 4.4 %

TNXP stock opened at $0.39 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $14.08. The firm has a market capitalization of $72.01 million, a PE ratio of -0.01 and a beta of 2.23. The company’s 50 day simple moving average is $0.22 and its 200-day simple moving average is $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Equities analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

See Also